AUTHORS
Mazyar Shadman, MD, MPH, Norah Akinola2, Seema Ali Bhat, MD3, Jennifer R. Brown, MD, PhD4, John Byrd, MD5, Ja Min Byun, MD6, Maria Del Rosario Custidiano, MD7, Barbara Eichhorst, MD8, Gamal Mohamed Fathy, MD9, Romina Gamberale, MD, PhD10, Alina S. Gerrie, MD, FRCPC, MPH11, William Mawalla12, Rebbecca Mwakichako, MD13, Miguel Arturo A. Pavlovsky, MD14, Lauren Pretorius15, John F. Seymour, MBBS, PhD16, Tanya Siddiqi, MD17, Abraham Mullasseril Varghese, PhD, FRCPath18, Jennifer A. Woyach, MD19, Danmei Xu20, Mohamed Yassin, MBBS, MSc, ABIM ,FRCP, MSC, FACP, FRCPath21, Anna Schuh, MD22
AFFILIATIONS
1 Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington, United States
2 Obafemi Awolowo University, Ile-Ife, Nigeria
3 The Ohio State University, Columbus, Ohio, United States
4 Dana Farber Cancer Institute, Harvard University, Boston, United States
5 UPMC Hillman Cancer Center, Pittsburgh, United States
6 Seoul National University College of Medicine, Seoul, Korea, Rep. of South
7 Instituto Alexander Fleming, Cramer, Argentina
8 University Hospital Cologne, Cologne, Germany
9 Nasser institute for research and treatment, Cairo, Egypt
10 Laboratorio de Inmunología Oncológica, IMEX-CONICET-ANM, Buenos Aires, Argentina
11 University of British Columbia, Vancouver, Canada
12 Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
13 Moi county Referral Hospital, Voi, Kenya
14 FUNDALEU, clinical research center, Buenos Aires, Argentina
15 Campaigning for Cancer, JOHANNESBURG, South Africa
16 Peter MacCallum Cancer Centre, Melbourne, Australia
17 City of Hope, Duarte, United States
18 Leeds teaching hospitals NHS trust, Leeds, United Kingdom
19 The Ohio State University, Columbus, Ohio, United States
20 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
21 ational Center for Cancer Care and Research Hamad Medical Corporation, Doha, Qatar
22 Oxford University, Oxford, United Kingdom
ABSTRACT
Introduction: Advances in molecular diagnostics and targeted therapies have transformed chronic lymphocytic leukemia (CLL) care. However, access remains highly variable, particularly in low- and middle-income countries (LMICs). Understanding these disparities is essential to inform resource-adapted recommendations and equitable CLL care.
Methods: We conducted a cross-sectional electronic survey as part of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Global Partnership. Survey participants were identified following multiple working group discussions after which regional representatives nominated hematology/CLL experts from LMICs across Africa, Asia, Latin America, and Eastern Europe based on their expertise and involvement in CLL care. This widely advertised survey assessed healthcare infrastructure, financing, and access to diagnostics, prognostic testing, and available therapies. Responses were generally categorized as: unavailable (0%), rare (<25%), frequent (>=25% to >=75%), and always (100%). Data were summarized descriptively.
Results: Surveys were sent to representatives from 42 LMIC countries, of which 29 (71%) were completed by hematologists (86.2%), medical oncologists (6.9%), pathologist or molecular/genomic specialists (3.4%) or other (3.4%). Peripheral blood morphology was used rarely in 3.4% (1/29), frequently in 24.1% (7/29) and always in 72.4% (21/29). Flow cytometry was used rarely in 20.7% of countries (6/29), frequently in 34.5% (16/29), and always in 44.8% (13/29). Rare availability was reported for bone marrow morphology in 27.6% of countries (8/29), computed tomography (CT) in 24.1% (7/29), and ultrasound in 13.8% (4/29). Positron emission tomography (PET-CT) was never available in 31% (9/29) and used frequently or always in only 13.8%. Prognostic tests that were never available included FISH in 10.3% (3/29), conventional karyotype in 13.8% (4/29), TP53 testing in 17.2% (5/29), and IGHV testing in 20.7% (6/29). Rare use was reported for FISH in 41.4% (12/29), karyotype in 55.2% (16/29), TP53 in 51.7% and IGHV testing in 37.9%.
For therapeutic agents, frequent or always use was reported for chlorambucil in 58.6% (17/29) of countries, bendamustine in 58.6% (17/29), fludarabine in 62.1% (18/29), cyclophosphamide in 72.4% (21/29), and rituximab in 93.1% (27/29) of countries. Across the responding countries unavailable or rare use was reported for ibrutinib in 34.5% (10/29) of countries, acalabrutinib in 58.6% (17/29), zanubrutinib in 82.1% (23/28), pirtobrutinib in 100% (29/29), venetoclax in 55.2% (16/29), and obinutuzumab in 82.8% (24/29) of countries. CAR T-cell therapy was not available in any of the responding countries for CLL. Chemotherapy agents were predominantly available as non-brand formulations: chlorambucil (57.7% non-brand vs 19.2% brand-only), cyclophosphamide (55.2% vs 20.7%), fludarabine (53.6% vs 28.6%), and bendamustine (48.1% vs 29.6%). Rituximab was brand-only in 41.4%, non-brand in 34.5%, and both in 24.1%. Obinutuzumab, acalabrutinib, zanubrutinib, venetoclax, and ibrutinib were brand-only in 82.6%, 68.2%, 66.7%, 45.8%, and 50% of countries, respectively, while non-brand was available in 13.0%, 22.7%, 16.7%, 33.3%, and 46.2%. Across these five drugs combined (Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Venetoclax), 32.2% of responses reported public funding (always/sometimes), and 44.9% reported private insurance coverage.
Discussion: In the LMICs surveyed, a marked access gradient exists across the CLL care continuum, with disparities increasing in diagnostics to molecular testing and, most prominently, to novel therapies. While foundational diagnostics and chemoimmunotherapy were broadly available, access to guideline-recommended prognostic testing and targeted therapies was substantially more limited. These findings support the need for resource-adapted recommendations and evidence-based policy frameworks to improve equitable CLL care.
DISCLOSURES
Mazyar Shadman, MD, MPH: Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current equity holder in private company; Janssen - Research Funding; AstraZeneca - Research Funding; Sana Biotechnology - Research Funding; Nurix - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Morphosys/Incyte - Research Funding; AbbVie - Research Funding; Beigene - Research Funding; Genmab - Research Funding; Incyte - Research Funding; Vincerx - Research Funding; Mustang Bio - Research Funding; Merck - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Legend Bio - Research Funding; AbbVie - Research Funding; Genetech - Research Funding; Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Mustang Bio - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Legend Bio - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Kite, A Gilead company - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); Fate therapeutics - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)